Spinal Muscular Atrophy

What is spinal muscular atrophy?

Spinal muscular atrophy is a genetic condition that affects the nerve cells in the spinal cord that control voluntary muscle movement. These nerve cells are called motor neurons. In people with spinal muscular atrophy, motor neurons gradually break down and die, which means the signals telling muscles to move become weaker or stop altogether. Over time, the muscles themselves shrink and weaken because they are no longer being used and stimulated. This shrinking of muscle tissue is what doctors mean by the word atrophy.

To answer the common question “what is spinal muscular atrophy” in the simplest terms: it is an inherited disease of the motor nerves that causes progressive muscle weakness, most noticeably in the muscles closest to the center of the body, such as the shoulders, hips, thighs, and upper back. Muscles used for breathing and swallowing can also be affected, particularly in the more severe forms.

Spinal muscular atrophy most often appears in infancy or early childhood, but milder forms can first cause symptoms in adolescence or adulthood. It affects people of all ethnic backgrounds and both sexes. Doctors classify the condition into several types, usually numbered 0 through 4, based on the age when symptoms begin and the highest level of motor ability a person reaches, such as sitting or walking without support. In general, the earlier the symptoms start, the more severe the condition tends to be. Importantly, spinal muscular atrophy affects the muscles and motor nerves, not intelligence; children and adults with the condition typically have normal thinking, learning, and social abilities.

Symptoms of spinal muscular atrophy

Spinal muscular atrophy symptoms vary widely depending on the type and the age at which the condition begins. The common thread across all types is muscle weakness that tends to be more pronounced in the muscles nearest the trunk (the proximal muscles) than in the hands and feet.

Common signs and symptoms include:

• Muscle weakness, usually symmetrical (affecting both sides of the body equally) and worse in the hips, thighs, shoulders, and upper arms
• Low muscle tone (hypotonia), sometimes described in babies as feeling “floppy” when held
• Delayed motor milestones in infants and children, such as difficulty holding up the head, rolling over, sitting, standing, or walking at the expected age
• Loss of motor skills that were previously achieved, such as a child who could sit or walk becoming unable to do so
• Muscle wasting, meaning visible thinning of the muscles over time
• Twitching of the tongue (fasciculations), a small trembling movement that doctors often look for in infants
• Difficulty swallowing or feeding, including weak sucking in babies, choking, or poor weight gain
• Breathing problems, such as weak cough, shallow breathing, or frequent chest infections, because the muscles between the ribs can be weak
• Curvature of the spine (scoliosis), which often develops in children who cannot stand or walk
• Tremor of the fingers and fatigue with activity, more typical of the milder, later-onset forms

How these symptoms appear depends heavily on the type. In the most severe infant-onset form (often called type 1), symptoms usually appear within the first six months of life. Affected babies typically cannot sit without support and often have serious feeding and breathing difficulties. In type 2, symptoms usually begin between roughly six and eighteen months of age; children can typically sit independently but usually cannot stand or walk without help. Type 3 begins after eighteen months and sometimes not until later childhood; these children can usually walk, although they may lose that ability over time and often have trouble running, climbing stairs, or rising from the floor. Type 4 is the adult-onset form and is generally the mildest, causing slowly progressive weakness that usually begins after age 20 or 30. Sensation, meaning the ability to feel touch, pain, and temperature, is not affected in spinal muscular atrophy.

Causes and risk factors

Spinal muscular atrophy causes are genetic. The most common form of the condition is caused by changes (mutations) in a gene called SMN1, which stands for survival motor neuron 1. This gene carries the instructions for making a protein that motor neurons need to survive and function. When both copies of the SMN1 gene are missing or faulty, the body cannot make enough of this protein, and motor neurons gradually die.

Humans also carry a very similar “backup” gene called SMN2. This gene produces a small amount of working survival motor neuron protein, but usually not enough to fully protect the motor neurons. The number of SMN2 copies a person carries varies from one individual to another, and in general, having more copies of SMN2 is associated with milder symptoms and later onset. This is one reason the condition ranges from very severe in infancy to relatively mild in adulthood.

Spinal muscular atrophy is usually inherited in what is called an autosomal recessive pattern. In plain terms, this means a child develops the condition only when they inherit a faulty copy of the SMN1 gene from both parents. People who carry one faulty copy and one working copy are called carriers. Carriers do not have symptoms and are often unaware of their carrier status. When two carriers have a child together, in each pregnancy there is roughly a one-in-four chance that the child will have spinal muscular atrophy, a one-in-two chance the child will be a carrier, and a one-in-four chance the child will inherit two working copies.

The main risk factor, therefore, is family history: having a relative with spinal muscular atrophy or known carriers in the family increases the likelihood that future children could be affected. Because carriers are relatively common in the general population, however, many affected children are born to families with no previous history of the condition. Rare forms of spinal muscular atrophy are caused by changes in other genes and may follow different inheritance patterns; a genetic specialist can explain these in individual cases. The condition is not caused by anything a parent did or did not do during pregnancy, and it is not contagious.

Diagnosis

Spinal muscular atrophy diagnosis today rests primarily on genetic testing. If a doctor suspects the condition based on symptoms such as low muscle tone, delayed milestones, or progressive weakness, the standard confirmatory test is a blood test that looks for missing or faulty copies of the SMN1 gene. This test is highly reliable for the most common form of the disease and, in many cases, makes more invasive testing unnecessary. The same laboratory analysis can often count the number of SMN2 copies, which helps doctors estimate how the condition may behave and guide treatment planning.

Other tests that may be used, especially when the genetic result is unclear or a different muscle or nerve disorder is being considered, include:

• Physical and neurological examination, in which the doctor assesses muscle strength, muscle tone, reflexes (which are often reduced or absent in spinal muscular atrophy), and motor milestones
• Electromyography (EMG), a test that uses small needles to measure the electrical activity of muscles and can show patterns typical of motor neuron loss
• Nerve conduction studies, which measure how quickly electrical signals travel along nerves
• Blood tests for creatine kinase, a muscle enzyme that can help distinguish spinal muscular atrophy from certain muscle diseases
• Muscle biopsy, the removal of a tiny sample of muscle for examination under a microscope; this is rarely needed now that genetic testing is widely available

In many countries, spinal muscular atrophy is now included in newborn screening programs, in which a few drops of blood taken shortly after birth are tested for the SMN1 gene change. Early identification matters because treatment started before symptoms appear, or very soon after, generally leads to better outcomes than treatment started later. Genetic testing is also available for prospective parents who want to know whether they are carriers, and prenatal testing can be discussed with a genetic counselor when both parents are known carriers. Diagnosis and long-term management are typically coordinated by neurology specialists; at Acibadem, for example, this condition falls under the neurology department, working together with pediatric, respiratory, orthopedic, and rehabilitation teams.

Treatment options

Spinal muscular atrophy treatment has changed substantially in recent years. Although there is currently no cure, disease-modifying medicines now exist that target the underlying genetic cause, and comprehensive supportive care remains essential for protecting breathing, nutrition, mobility, and quality of life. Treatment plans are individualized based on the person’s age, type of spinal muscular atrophy, current abilities, and overall health.

Disease-modifying medicines

Several medicines are approved in many countries that aim to increase the amount of survival motor neuron protein in the body:

• Nusinersen is given by injection into the fluid around the spinal cord (an intrathecal injection). It works by helping the backup SMN2 gene produce more functional protein. It is given as a series of initial doses followed by ongoing maintenance doses.
• Risdiplam is a liquid medicine taken by mouth every day. It also works by increasing the amount of functional protein produced from the SMN2 gene.
• Onasemnogene abeparvovec is a one-time gene therapy given by intravenous infusion, generally to young children. It delivers a working copy of the SMN1 gene to motor neurons.

These medicines can slow or stop disease progression and, in many cases, improve motor function, particularly when started early. They do not reverse motor neuron loss that has already occurred, which is why timing matters. Eligibility, expected benefit, and possible side effects differ for each medicine, and your medical team will discuss which option, if any, is appropriate in your situation.

Supportive and rehabilitative care

Supportive care is a cornerstone of treatment for every type of spinal muscular atrophy and often involves a multidisciplinary team:

• Respiratory care, including breathing exercises, cough-assistance devices, and, when needed, non-invasive ventilation (a mask that supports breathing, often used during sleep). Vaccinations and prompt treatment of chest infections are also important.
• Nutritional support, such as guidance from a dietitian, swallowing assessments, and in some cases a feeding tube to ensure safe and adequate nutrition.
• Physical and occupational therapy to maintain flexibility, prevent joint stiffness (contractures), support motor development, and adapt daily activities. Braces, standing frames, and wheelchairs may be recommended to support mobility and independence.
• Orthopedic care and surgery, particularly for scoliosis. When spinal curvature becomes severe, spinal surgery may be considered to improve sitting posture and protect breathing capacity. Surgery for hip problems or contractures is sometimes discussed as well.

Monitoring and watchful waiting

Some individuals identified through newborn screening with a genetic result suggesting a very mild course, and some adults with slowly progressive symptoms, may be monitored closely before or alongside treatment decisions. Regular follow-up allows the care team to detect any change early and adjust the plan. Decisions about starting, continuing, or changing treatment are made together with the patient and family, weighing potential benefits, burdens, and personal goals.

Living with spinal muscular atrophy and outlook

The outlook for people with spinal muscular atrophy varies widely and depends mainly on the type, the age at diagnosis, and how early treatment begins. Historically, the severe infant-onset form was associated with a very short life expectancy, while people with milder types often lived into adulthood with varying degrees of disability. The availability of disease-modifying medicines has improved outcomes for many patients, and children treated very early, before symptoms develop, often achieve motor milestones that would previously have been unlikely. However, responses vary from person to person, and no treatment can guarantee a specific outcome.

Living well with spinal muscular atrophy usually means ongoing, coordinated care: regular reviews of breathing and nutrition, physical therapy, attention to bone and spine health, and timely equipment adjustments as needs change. Many people with milder forms attend school, work, and raise families, sometimes with mobility aids or workplace adaptations. Because the condition does not affect intelligence, educational and social support should aim for full participation. Emotional and psychological support matters too; living with a progressive condition can be demanding for patients and caregivers alike, and counseling or connection with patient support organizations can help. Genetic counseling is often valuable for families planning future pregnancies.

Frequently asked questions

What is spinal muscular atrophy in simple terms?

Spinal muscular atrophy is an inherited condition in which the nerve cells that control muscle movement gradually stop working. As a result, muscles become weak and shrink over time. It most often appears in babies and young children, but milder forms can begin in adolescence or adulthood. It affects movement, and in severe forms breathing and swallowing, but it does not affect intelligence.

Can spinal muscular atrophy be cured?

There is currently no cure for spinal muscular atrophy. However, several approved medicines can address the underlying genetic problem and, in many cases, slow or stop the disease and improve function, especially when started early. Supportive care for breathing, nutrition, and mobility also plays a major role in health and quality of life. Research into new and improved treatments is ongoing.

How serious is spinal muscular atrophy?

Severity varies greatly. The most severe form begins in early infancy and can be life-threatening because of breathing and feeding difficulties, particularly without treatment. Milder forms cause weakness that progresses slowly over years or decades, and many affected people live full adult lives. Early diagnosis and early treatment generally improve the outlook, but the course differs from person to person, and your medical team is best placed to discuss what to expect in an individual case.

What are the first symptoms of spinal muscular atrophy?

In infants, early spinal muscular atrophy symptoms often include noticeable floppiness, weak movements of the arms and legs, difficulty holding up the head, weak crying or sucking, and missed motor milestones. In older children and adults, the first signs are often difficulty running, climbing stairs, or getting up from the floor, along with muscle weakness around the hips and shoulders. Anyone noticing these signs should discuss them with a doctor rather than trying to self-diagnose.

How is spinal muscular atrophy diagnosed?

Diagnosis is confirmed with a genetic blood test that checks for missing or faulty copies of the SMN1 gene. This test is reliable for the most common form of the disease. Doctors may also perform a neurological examination and, in unclear cases, tests such as electromyography (a measurement of the muscles’ electrical activity). In many countries, newborn screening programs can now identify the condition shortly after birth, before symptoms appear.

Is spinal muscular atrophy passed down in families?

Yes, in most cases. The common form is inherited when a child receives a faulty copy of the SMN1 gene from both parents, who are usually healthy carriers without symptoms. When both parents are carriers, each pregnancy carries roughly a one-in-four chance of an affected child. Carrier testing and genetic counseling are available for people with a family history or those planning a pregnancy who want to understand their risk.

Can adults develop spinal muscular atrophy?

Yes. The adult-onset form, often called type 4, typically begins after age 20 or 30 and is generally the mildest type. It usually causes slowly progressive weakness in the muscles of the hips, thighs, and shoulders, sometimes with tremor or fatigue. Breathing and swallowing are less commonly affected than in childhood-onset forms. Adults with unexplained progressive muscle weakness should be evaluated by a neurologist, as several other conditions can cause similar symptoms.

When to see a doctor

Talk with a doctor promptly if you notice possible signs of spinal muscular atrophy in yourself or your child, such as a baby who seems unusually floppy, is not reaching motor milestones, or feeds poorly, or a child or adult with progressive difficulty walking, climbing stairs, or rising from a chair. Early evaluation matters because early treatment is generally more effective. If the condition has already been diagnosed, keep scheduled follow-up visits so the care team can monitor breathing, nutrition, and spine health.

Seek urgent medical attention if any of the following red-flag signs occur:

• Difficulty breathing, rapid or labored breathing, pauses in breathing, or bluish color of the lips or skin
• Severe swallowing problems or choking, especially if food or liquid seems to go into the airway
• Signs of a chest infection, such as fever with cough, increased mucus, or worsening breathlessness, since weak cough muscles make infections riskier
• A sudden or rapid loss of strength or motor abilities, such as no longer being able to sit, stand, or walk as before
• Poor feeding, dehydration, or unexplained weight loss in an infant or child
• Excessive daytime sleepiness or morning headaches, which can be signs of weakened breathing during sleep

These warning signs do not always mean an emergency related to spinal muscular atrophy, but they should be assessed quickly by a medical professional. When in doubt, it is safer to seek care early, particularly for infants and for anyone with known breathing or swallowing weakness.